2,753 press releases indexed under healthcare.
WASHINGTON, July 14, 2026 /PRNewswire/ -- A coalition of public health organizations, pediatricians and parents today filed a federal lawsuit challenging the Food and Drug Administration's new enforcement policy that allows e-cigarette and nicotine pouch products to be marketed and sold...
National convening will connect families, uplift Baltimore leaders and strengthen pathways for the next generation through two free public events WASHINGTON, July 14, 2026 /PRNewswire/ -- Thousands of families will arrive in Baltimore from July 21–26 as Jack and Jill of America,...
MUNICH, GERMANY and BANGALORE, INDIA - July 14, 2026 ( NEWMEDIAWIRE ) - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE, “OneSource”), a multi-modality specialty pharma CDMO, today announced a strategic manufacturing partnership for biosimilars. Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its state-of-the-art biologics’ facility in Bangalore, India. The collaboration brings together Formycon’s biosimilar development excellence with OneSource’s end-to-end biologics manufacturing expertise to support Formycon’s biosimilar programs for global markets. Dr. Stefan Glombitza, Chief
MELVILLE, N.Y., July 14, 2026 /PRNewswire/ -- Micross Components, Inc. ("Micross" or the "Company"), a global provider of high-reliability microelectronic products and services for aerospace, defense, space, medical, and industrial applications, and a portfolio company of Behrman Capital,...
ALHAMBRA, Calif., July 14, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality,...
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis FRIENDSWOOD, Texas, July 14, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health...
Eminent Spine, a leader in advanced 3D implant technology, releases the early clinical and implant results of the world's first FDA 510(k) approved 3D printed titanium pedicle screw. The proprietary 3D printed pedicle screw, designed and manufactured by Eminent Spine received FDA 501(k) clearance on April 28, 2025. The new novel 3D titanium printing cutting edge technology surpassed the FDA biomechanical testing critria. [PR.com]
Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years
LOS ANGELES, CA - July 14, 2026 ( NEWMEDIAWIRE ) - For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII) , a developer of innovative surgical robotic technologies, who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities. Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms, remaining central to the company’s lon
Multidisciplinary initiative increased naloxone co-prescribing with outpatient opioid prescriptions from
Cosmos Health has now repurchased a total of approximately 4,488,000 shares for approximately $941,000.
No matter the ingredient, Intermountain Health Dermatologists still emphasize importance of broad-spectrum sunscreens to protect from both UVA and UVB rays. The post Intermountain Health Dermatologist Discusses New FDA-Approved Sunscreen Ingredient first appeared on